文献速递骨软组织肉瘤与黑色素瘤

分子特征可预测局限性尤因肉瘤预后:儿童肿瘤协作组报告

Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
PubMed 文献 · J Clin Oncol · 2025-11-03

单因素分析显示TP53突变、STAG2突变和复发拷贝数变异与复发累积发生率升高相关,多因素分析中仅STAG2突变保持预后价值。

要点

  • STAG2突变是局限性尤因肉瘤独立预后不良因素。
  • TP53突变和复发拷贝数变异单因素与复发风险升高相关。
  • 多数病例可用两张FFPE切片完成分子检测。

核心结论

  • 在COG治疗试验中前瞻性验证了局限性尤因肉瘤的分子预后特征,STAG2突变患者复发风险高。

研究设计与样本

  • 检测经典融合、复发拷贝数变异及TP53、STAG2改变,并分析STAG2蛋白表达缺失。

主要发现

  • 282例(80.3%)检出尤因肉瘤经典融合。
  • TP53和STAG2致病突变分别见于5.1%和7.6%的患者,63.1%存在复发拷贝数变异。

临床怎么用

  • 对局限性尤因肉瘤患者可检测STAG2突变以识别高复发风险人群。
  • 分子检测多数情况下可用两张FFPE切片完成,便于临床开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Identifying discrete subgroups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children's Oncology Group (COG) biology study AEWS18B1-Q was to molecularly characterize patients with localized EWS on prospective modern-day trials. PATIENTS AND METHODS: We analyzed clinical and molecular features from patients with localized EWS enrolled on frontline COG trials. All patients had available formalin-fixed paraffin-embedded (FFPE) tissue, frozen tissue, or whole-genome-amplified material. Sequencing was performed for identification of canonical fusions, recurrent copy number alterations (CNAs), and alterations in TP53 and STAG2. Available tissue was analyzed for loss of STAG2 protein expression. Molecular features were evaluated for their association with cumulative incidence of relapse in univariate and multivariable analyses. RESULTS: Three hundred fifty-one patients had sufficient tissue, which in most cases was extracted from two FFPE slides. EWS canonical fusions were identified in 282 patients (80.3%). Pathogenic mutations in TP53 and STAG2 were identified in 5.1% and 7.6% of patients, respectively. A total of 63.1% of patients were found to have recurrent CNAs. In univariate analysis, there was an increased cumulative incidence of relapse in patients with TP53 mutation (5-year cumulative incidence of relapse 43%, 95% CI [17% to 67%] v 22%, 95% CI [17% to 27%]; Gray's test P = .039), STAG2 mutation (53%, 95% CI [29% to 73%] v 21%, 95% CI [16% to 26%]; P < .001), and recurrent CNAs (30%, 95% CI [22% to 37%] v 16%, 95% CI [9% to 24%]; P = .005). In a multivariable analysis, STAG2 mutation was the only molecular biomarker that remained prognostic. CONCLUSION: This is a prospective validation of the molecular prognostic features of patients with localized EWS receiving standard-of-care therapy on therapeutic clinical trials. Building on previous work, patients with STAG2 mutations were at high risk of relapse.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Gillani R, Shulman DS, DelRocco NJ, et al. Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2025. PMID: 41183255. doi:10.1200/JCO-25-00157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。